A General Session held January 20 during the 2018 Gastrointestinal Cancers Symposium provided a comprehensive overview of early-onset CRC, including results of a study focused on the age distribution of tumor gene expression in patients with stage II/III colon cancer.
The phase III CELESTIAL trial met its primary endpoint by demonstrating a survival advantage with cabozantinib in patients with advanced hepatocellular carcinoma (HCC) that progressed following prior systemic therapy.
Use of the oral fluoropyrimidine-based chemotherapy S-1 in combination with gemcitabine yielded similar efficacy and a more favorable and convenient tolerability profile versus cisplatin and gemcitabine in patients with advanced biliary tract cancer.
Results of the randomized controlled TACTICS trial demonstrate that transcatheter arterial chemoembolization (TACE) in combination with sorafenib significantly improved progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC), as compared with TACE alone.
Five important talks delivered the morning of January 19 during the 2018 Gastrointestinal Cancers Symposium covered diverse topics that provide insight into future diagnostic, management, and research directions in hepatocellular carcinoma
Results of the global, randomized, double-blind, placebo-controlled, phase III RAINFALL trial established the statistical benefit of ramucirumab added to standard chemotherapy for patients with previously untreated metastatic gastric or gastroesophageal junction adenocarcinoma.
Two studies that investigated the ways in which neoadjuvant chemoradiation therapy is delivered before surgery and how different parameters influence survival outcomes raise some questions and suggest that CRT may exert unintended consequences.
Dr. Flavio G. Rocha reviews liver-directed therapy for advanced intrahepatic cholangiocarcinoma, which can be difficult to manage because of several factors including late diagnosis, early metastatic spread, and potential for liver dysfunction.
Dr. Davendra P. S. Sohal discusses the management of metastatic pancreatic cancer, specifically the advances made since ASCO issued guidelines in 2016 for management of metastatic pancreatic cancer and the future direction for treatment.
Dr. Shailesh V. Shrikhande of the Tata Memorial Centre, in Mumbai, India, discusses gastrointestinal cancers in India and how the steps being taken to address them align with the theme of this year's Symposium.